1477: Ocumension Therapeutics - Summary | Jitta
Jitta Wealth
NEW
Log in
Sign up
×
Log in

Ocumension Therapeutics

HKG:1477

SummaryFactSheetFinancial
Price
HK$4.51
Loss Chance
46.3%
4.71JITTA SCORE
23.13%Over Jitta Line
Jitta Ranking
Pharmaceuticals
6 / 51
Health Care
37 / 240
Hong Kong
?
326 / 2,581
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Related
Pak Fah Yeow International Limited
HKG:0239
5.36
HK$2.38
36.20%
CSPC Pharmaceutical Group Limited
HKG:1093
6.81
HK$8.36
130.63%
Sino Biopharmaceutical Limited
HKG:1177
7.38
HK$4.98
110.99%
Consun Pharmaceutical Group Limited
HKG:1681
8.01
HK$15.21
33.89%
Simcere Pharmaceutical Group Limited
HKG:2096
6.62
HK$10.38
39.16%
Jitta Factors
Growth Opportunity (63)
Recent Business Performance (75)
Financial Strength (43)
Return to Shareholders (3)
Competitive Advantage (61)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
SG&A to SalesDecreasing Every Year
Revenue and EarningEarning loss detected in 2025
CapExVery High
Key Stats
Jitta Score
Jitta Line
4.71
23.13%
4.36
98.47%
3.82
382.56%
Pharmaceuticals
5.36
36.20%
6.81
130.63%
7.38
110.99%
COMPANY DESCRIPTION
Ocumension Therapeutics, together with its subsidiaries, engages in the research, discovery, development, and commercialization of ophthalmic therapies in China. The company offers various ophthalmic drugs for the treatment of chronic non-infectious uveitis, wet age-related macular degeneration, diabetic macular edema, choroidal neovascularization, dry eye disease, glaucoma, allergic and bacterial conjunctivitis, fungus disease, and anti-inflammatory, as well as postoperative ocular inflammation, paralysis of ciliary muscle, and pupil dilation, as well as eyelid and periocular cleansing. It also develops drugs in Phase III clinical trial, including OT-101 for myopia, OT-802 for presbyopia, OT-211 for dry eye disease, and OT-301 for glaucoma; and drugs in Phase I/II clinical trial, such as OT-703 for diabetic macular edema, OT-202 for dry eye disease, and OT-601-C for the treatment of ocular inflammation. In addition, the company engages in the development of drugs in preclinical stage comprising OT-701 for wet age-related macular degeneration, OT-1601 for retinitis pigmentosa and dry age-related macular degeneration, OT-1602 for optic neuritis, and OT-503 for dry eye disease. Further, it is involved in trading of pharmaceutical products; and plant construction. The company was founded in 2017 and is based in Suzhou, China.
www.ocumension.com
About UsCareersHelp CenterLibraryTermsPrivacyContact UsPress

Jitta Dot Com Co., Ltd. is the owner of the copyright of JITTA SCORE, JITTA LINE, JITTA SIGNS, JITTA FACTORS, JITTA LOSS CHANCE and JITTA RANKING. By accessing or using Jitta, you agree to comply with our Terms of Use and agree not to redistribute the information.

All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Any historical returns, backtest statistics or probability projections may not reflect future performance. Neither Jitta nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Fundamental data of companies, historical data, daily updates, financial statements, dividend data and index data are provided by S&P Global Market Intelligence. All stock prices are updated at the end of the day.